Join our daily newsletter At The Bell to receive exclusive market insights
- Starpharma (SPL) signs a new DEP research agreement with MSD, the trade name of Merck Sharp & Dohme
- Under this agreement, Starpharma will design and synthesise a number of DEP dendrimer conjugates for MSD to test and characterise
- This new agreement follows the company signing a research agreement with MSD in February 2021 to research dendrimer-based antibody drug conjugates using its DEP technology
- Starpharma’s DEP technology works as a drug delivery mechanism to make sure the drug is delivered to the right part of the body at the right time
- SPL shares are down a slight 0.68 per cent and trading at 74.5 cents at 12:48 pm AEST
Starpharma (SPL) has signed a new DEP research agreement with MSD, the trade name of Merck Sharp & Dohme.
Under this agreement, Starpharma will design and synthesise a number of DEP dendrimer conjugates for MSD to test and characterise.
Research fees are payable to Starpharma for completed work and the company is not required to fund the program.
The agreement runs for an initial 12 months and each company will keep ownership of their own intellectual property.
In February 2021, Starpharma signed a research agreement with MSD to research dendrimer-based antibody drug conjugates (ADCs) using its DEP technology.
ADCs are antibodies that are linked to one or more drug molecules and when it meets its targeted cell, such as cancer, the drug is released to kill it.
Starpharma’s DEP technology works as a drug delivery mechanism to make sure the drug is delivered to the right part of the body at the right time.
“We are very pleased to add this new DEP ADC program with MSD and to continue building on our partnership with them in such an innovative and valuable area,” CEO Dr Jackie Fairley said.
“This new DEP program underlines the potential clinical and commercial value our DEP
technology can deliver.”
Shares in Starpharma were down a slight 0.68 per cent and were trading at 74.5 cents at 12:48 pm AEST.
